JCR Pharmaceuticals announced yesterday that it has launched its biosimilar agalsidase beta product, referencing Fabrazyme, in Japan for the treatment of Fabry disease. JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
JCR Pharmaceuticals announced yesterday that it has launched its biosimilar agalsidase beta product, referencing Fabrazyme, in Japan for the treatment of the lysosomal storage disorder (LSD) Fabry disease (FD). JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
The product, Agalsidase Beta BS IV Infusion, which will be available in 5-mg and 35-mg vials, was approved by Japan’s Ministry of Health, Labor, and Welfare in September 2018. In its announcement of the product’s availability, JCR noted that not only is the product the first biosimilar agalsidase beta, it is also the first product for the treatment of an LSD that will be produced domestically in Japan.
Japanese regulators approved the product on the basis of a data package that included findings from a nonclinical evaluation of the product in comparison with its reference that determined that the amino acid sequence of the products was identical. A higher-order assessment of the structures revealed both molecules to have similar structural properties and comparable enzyme activity. The biosimilar had a similar glycosylation profile to the reference, but the biosimilar demonstrated slightly better cellular uptake of enzymes than the reference did (this fact did not affect pharmacokinetics of efficacy, however).
Like its reference, the biosimilar product is a recombinant human alpha-galactosidase A enzyme replacement therapy for FD, which is a rare inherited disorder that affects 1 in 40,000 to 60,000 men. (While FD can also affect women, its prevalence in female patients is not known.) FD stems from a mutation in the alpha-galactosidase A gene that causes a buildup of globotriaosylceramide in cells. This buildup can adversely affect the functioning of the heart, kidneys, and other organs and lead to cardiac disease, stroke, renal failure, and early death.
Given how critical treatment with agalsidase beta is to control FD, the availability of a biosimilar option will be welcome to patients, who in the past have faced shortages of the reference Fabrazyme. In 2009, a manufacturing process introduced viral contamination into the Sanofi Genzyme reference drug, sparking a global shortage of this crucial therapy.
During the shortage, patients were instructed by the European Medicines Agency to reduce their dosages, but after an increased rate of serious adverse events was observed among FD patients who followed directions to reduce their doses, patients were subsequently asked to switch to other treatment options. In the United States, patients with FD unsuccessfully petitioned the US government to force Sanofi Genzyme to license its patent for Fabrazyme to biosimilar developers in order to create further supply of the treatment.
To date, JCR has not announced whether it will seek European or US regulatory authorization for the biosimilar.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.